We are live on ! Find out more
AYTU icon

AYTU BioPharma
AYTU

27 hedge funds and large institutions have $5.99M invested in AYTU BioPharma in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more capital invested

Capital invested by funds: $5.46M → $5.99M (+$537K)

2.17% more ownership

Funds ownership: 32.23% → 34.4% (+2.2%)

0% more funds holding

Funds holding: 27 → 27 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6

Holders
27
Holders Change
–
Holders Change %
0%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
6
Closed
3
Calls
$238K
Puts
–
Net Calls
+$238K
Net Calls Change
+$238K

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$761K
2
Citadel Advisors
Citadel Advisors
Florida
+$29.1K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$25.1K
4
Renaissance Technologies
Renaissance Technologies
New York
+$8.45K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$4.09K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$42.2K
2
TRCT
Tower Research Capital (TRC)
New York
-$3.21K
3
UBS Group
UBS Group
Switzerland
-$2.17K
4
Morgan Stanley
Morgan Stanley
New York
-$1.87K
5
JP Morgan Chase
JP Morgan Chase
New York
-$241
Name Holding Trade Value Shares
Change 		Change in
Stake
NCM
1
Nantahala Capital Management
Connecticut
$3.17M – – –
SCM
2
Stonepine Capital Management
Oregon
$1.38M – – –
AC
3
Armistice Capital
New York
$736K +$761K +252,000 New
Renaissance Technologies
4
Renaissance Technologies
New York
$216K +$8.45K +2,800 +4%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$105K +$4.09K +1,356 +4%
Vanguard Group
6
Vanguard Group
Pennsylvania
$81.4K – – –
Dimensional Fund Advisors
7
Dimensional Fund Advisors
Texas
$68.5K +$25.1K +8,311 +55%
BlackRock
8
BlackRock
New York
$66.6K – – –
Citadel Advisors
9
Citadel Advisors
Florida
$63.5K +$29.1K +9,635 +79%
Northern Trust
10
Northern Trust
Illinois
$42.5K -$21 -7 -0%
Acadian Asset Management
11
Acadian Asset Management
Massachusetts
$41K – – –
Royal Bank of Canada
12
Royal Bank of Canada
Ontario, Canada
$10K +$1.74K +576 +21%
TRCT
13
Tower Research Capital (TRC)
New York
$5.73K -$3.21K -1,064 -35%
JP Morgan Chase
14
JP Morgan Chase
New York
$1.57K -$241 -80 -13%
Morgan Stanley
15
Morgan Stanley
New York
$1.28K -$1.87K -620 -58%
UBS Group
16
UBS Group
Switzerland
$899 -$2.17K -718 -70%
Osaic Holdings
17
Osaic Holdings
Arizona
$876 – – –
Wells Fargo
18
Wells Fargo
California
$362 -$121 -40 -24%
Bank of America
19
Bank of America
North Carolina
$269 +$127 +42 +84%
CIBC Private Wealth Group
20
CIBC Private Wealth Group
Georgia
$242 – – –
Group One Trading
21
Group One Trading
Illinois
$108 – – –
NA
22
NewEdge Advisors
Louisiana
$61 – – –
HNB
23
Huntington National Bank
Ohio
$58 – – –
US Bancorp
24
US Bancorp
Minnesota
$26 +$27 +9 New
CWM
25
CarsonAllaria Wealth Management
Illinois
$15 – – –
1
2

AYTU Hedge Fund Activity: Q2 2024 in Review

27 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q2 2024, worth a combined $5.99M — up 9.8% from $5.46M a quarter earlier.

Fund positioning in AYTU was balanced in Q2 2024: 3 funds opened new positions, 3 closed out, 6 added to existing stakes and 6 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $761K. The largest seller was Goldman Sachs, exiting entirely with an estimated $42.2K sold.

  • 27 institutional investors held AYTU BioPharma (AYTU) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $5.99M of AYTU BioPharma stock for Q2 2024, up 9.8% quarter-over-quarter.
  • 3 funds opened new AYTU BioPharma positions in Q2 2024 and 3 closed out, a net change of 0 holders.
  • The largest AYTU BioPharma buyer in Q2 2024 was Armistice Capital, an estimated $761K added.
  • The largest AYTU BioPharma seller in Q2 2024 was Goldman Sachs, an estimated $42.2K sold.

Based on aggregated 13F filings for Q2 2024.